INmune Total Liab vs Total Assets Analysis
| INMB Stock | USD 4.87 0.11 2.31% |
INmune Bio financial indicator trend analysis is infinitely more than just investigating INmune Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether INmune Bio is a good investment. Please check the relationship between INmune Bio Total Liab and its Total Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
Total Liab vs Total Assets
Total Liab vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of INmune Bio Total Liab account and Total Assets. At this time, the significance of the direction appears to have very strong relationship.
The correlation between INmune Bio's Total Liab and Total Assets is 0.88. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Total Assets in the same time period over historical financial statements of INmune Bio, assuming nothing else is changed. The correlation between historical values of INmune Bio's Total Liab and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of INmune Bio are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Total Liab i.e., INmune Bio's Total Liab and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.88 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Total Assets
Total assets refers to the total amount of INmune Bio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in INmune Bio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from INmune Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.At present, INmune Bio's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 710.64, whereas Selling General Administrative is forecasted to decline to about 6.4 M.
| 2010 | 2023 | 2024 (projected) | Interest Income | 77.7K | 69.9K | 62.2K | Net Interest Income | 77.7K | 69.9K | 62.2K |
INmune Bio fundamental ratios Correlations
Click cells to compare fundamentals
INmune Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
INmune Bio fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 24.5M | 40.7M | 99.9M | 81.8M | 57.0M | 41.6M | |
| Total Current Liabilities | 700.4K | 1.8M | 4.4M | 10.9M | 18.5M | 19.4M | |
| Total Stockholder Equity | 23.6M | 38.8M | 80.2M | 60.1M | 38.1M | 33.6M | |
| Net Tangible Assets | 7.1M | 22.2M | 63.7M | 43.6M | 50.1M | 52.6M | |
| Retained Earnings | (21.3M) | (33.4M) | (63.7M) | (91.0M) | (121.0M) | (115.0M) | |
| Accounts Payable | 692.1K | 1.5M | 3.8M | 5.2M | 7.9M | 8.3M | |
| Cash | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
| Cash And Short Term Investments | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
| Capital Surpluse | 44.8M | 72.1M | 143.9M | 151.8M | 174.6M | 183.3M | |
| Total Liab | 860.5K | 1.9M | 19.7M | 21.7M | 18.9M | 19.8M | |
| Total Current Assets | 7.8M | 24.0M | 82.6M | 64.7M | 39.9M | 27.2M | |
| Common Stock | 8.7K | 10.8K | 13.5K | 18K | 817K | 857.9K | |
| Net Debt | (6.8M) | (21.8M) | (59.6M) | (36.8M) | (25.4M) | (26.7M) | |
| Non Current Assets Total | 16.7M | 16.7M | 17.3M | 17.1M | 17.1M | 16.2M | |
| Net Receivables | 645.4K | 1.8M | 5.5M | 8.5M | 2.4M | 2.8M | |
| Common Stock Total Equity | 8.7K | 10.8K | 13.5K | 18K | 20.7K | 12.9K | |
| Common Stock Shares Outstanding | 10.3M | 12.0M | 16.1M | 17.9M | 18.0M | 14.8M | |
| Liabilities And Stockholders Equity | 24.5M | 40.7M | 99.9M | 81.8M | 57.0M | 46.8M | |
| Non Current Liabilities Total | 160.2K | 126.3K | 15.4M | 10.8M | 397K | 377.2K | |
| Other Current Assets | 769.3M | 220K | 2.3M | 4.1M | 1.7M | 1.6M | |
| Other Stockholder Equity | 44.9M | 72.1M | 143.9M | 151.8M | 159.1M | 85.4M | |
| Accumulated Other Comprehensive Income | (8.5K) | 10.7K | 1K | (699K) | (799K) | (759.1K) | |
| Net Invested Capital | 23.6M | 38.8M | 94.7M | 74.8M | 48.1M | 49.4M | |
| Net Working Capital | 7.1M | 22.2M | 78.2M | 53.8M | 21.5M | 29.0M | |
| Retained Earnings Total Equity | (21.3M) | (33.4M) | (63.7M) | (91.0M) | (81.9M) | (77.8M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.